Results of a multicenter outpatient burn study on the safety and efficacy of Dimac-SSD, a new delivery system for silver sulfadiazine.
Dimac with silver sulfadiazine (Dimac-SSD), a new silver sulfadiazine delivery system, was evaluated prospectively in a multicenter study for the treatment of outpatient burn injuries. The goal of this study was to evaluate the effect of Dimac-SSD on the microbiology of the burn wounds and to quantitate its clinical safety and efficacy. A total of 197 patients were evaluated. Eight (4%) of these patients did not complete the study. Six patients withdrew because of local discomfort caused by the Dimac-SSD and two patients were terminated because of technical problems. The mean +/- SD duration of treatment with Dimac-SSD was 12 +/- 8.5 days, during which time the mean number of dressing changes was 2.9 per patient. During treatment with Dimac-SSD, the burn wound bacterial flora remained stable and overgrowth with Pseudomonas species or Gram-negative bacilli did not occur. Only four (2%) patients developed clinical infections; thus the Dimac-SSD appeared to have good antimicrobial effectiveness. This dressing was not associated with any organ system or metabolic side-effects and patient discomfort during application and removal was minimal. Thus this new delivery system for silver sulfadiazine was associated with excellent wound healing, a low incidence of wound infections, reduced frequency for dressing changes, and excellent patient compliance.
Deitch
E A
EA
Department of Surgery, LSUMC, School of Medicine, Shreveport 71130-3932.
Sittig
K
K
Heimbach
D
D
Jordan
M
M
Cruse
W
W
Kahn
A
A
Achauer
B
B
Finley
R
R
Matsuda
T
T
Salisbury
R
R
D000179:Acrylates / Q000008:administration & dosage*; D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D001458:Bandages; D002056:Burns / Q000382:microbiology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D004121:Dimethyl Sulfoxide / Q000008:administration & dosage* / Q000097:blood; D004338:Drug Combinations / Q000008:administration & dosage; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008689:Methacrylates / Q000008:administration & dosage*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011446:Prospective Studies; D012834:Silver / Q000097:blood; D012837:Silver Sulfadiazine / Q000008:administration & dosage*; D013411:Sulfadiazine / Q000008:administration & dosage* / Q000097:blood; D014946:Wound Infection / Q000517:prevention & control*
D000179:Acrylates; C059435:Dimac-SSD; D004338:Drug Combinations; D008689:Methacrylates; D013411:Sulfadiazine; D012834:Silver; D011092:Polyethylene Glycols; D012837:Silver Sulfadiazine; D004121:Dimethyl Sulfoxide